Literature DB >> 21771960

Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.

Susanne Bonekamp1, Prashant Jolepalem, Mariana Lazo, Mehmet Akif Gulsun, Atilla P Kiraly, Ihab R Kamel.   

Abstract

PURPOSE: To determine the association of early changes in posttreatment apparent diffusion coefficient (ADC) and venous enhancement (VE) with tumor size change after transarterial chemoembolization (TACE) by using an investigational semiautomated software.
MATERIALS AND METHODS: This retrospective HIPAA-compliant study was approved by the institutional review board, with waiver of informed consent. Patients underwent magnetic resonance (MR) imaging at 1.5 T before TACE, as well as 1 and 6 months after TACE. Volumetric analysis of change in ADC and VE 1 month after TACE compared with pretreatment values was performed in 48 patients with 71 hepatocellular carcinoma (HCC) lesions. Diagnostic accuracy was evaluated with receiver operating characteristic (ROC) analysis, using tumor response at 6 months according to Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST as end points.
RESULTS: According to RECIST criteria, 6 months after TACE, 30 HCC lesions showed partial response (PR), 35 showed stable disease (SD), and six showed progressive disease (PD). Increase in ADC and decrease in VE 1 month after TACE were significantly different between PR, SD, and PD. At area under the ROC curve (AUC) analysis of the ADC increase, there was an AUC of 0.78 for distinguishing PR from SD and PD and an AUC of 0.89 for distinguishing PR and SD from PD. The AUC for decrease in VE was 0.73 for discrimination of PR from SD and PD and 0.90 for discrimination of PR and SD from PD.
CONCLUSION: Volumetric analysis of increase in ADC and decrease in VE 1 month after TACE can provide an early assessment of response to treatment. Volumetric analysis of multiparametric MR imaging data may have potential as a prognostic biomarker for patients undergoing local-regional treatment of liver cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771960     DOI: 10.1148/radiol.11102330

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  33 in total

1.  Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Susanne Bonekamp; John Eng; Diane Reyes; David Cosgrove; Neda Rastegar; Li Pan; Timothy M Pawlik; Ihab R Kamel
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

Review 2.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 3.  Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others.

Authors:  Mecit Kantarci; Berhan Pirimoglu
Journal:  J Gastrointest Cancer       Date:  2017-09

4.  Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE.

Authors:  Zhi Li; Tong-Qing Xue; Xiao-Yu Chen
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

5.  Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.

Authors:  Olivio F Donati; Richard Kinh Gian Do; Andreas M Hötker; Seth S Katz; Junting Zheng; Chaya S Moskowitz; Christopher Beattie; Karen T Brown
Journal:  Eur Radiol       Date:  2015-04-08       Impact factor: 5.315

6.  Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.

Authors:  David Bonekamp; Susanne Bonekamp; Vivek Gowdra Halappa; Jean-Francois H Geschwind; John Eng; Celia Pamela Corona-Villalobos; Timothy M Pawlik; Ihab R Kamel
Journal:  Eur J Radiol       Date:  2013-12-03       Impact factor: 3.528

7.  Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.

Authors:  C Floridi; F Pesapane; S A Angileri; D De Palma; F Fontana; F Caspani; A Barile; A Del Sole; C Masciocchi; G Lucignani; G Carrafiello
Journal:  Med Oncol       Date:  2017-09-05       Impact factor: 3.064

8.  Dynamic characteristics of MR diffusion-weighted imaging in a rabbit liver VX-2 tumor model.

Authors:  You-Hong Yuan; En-Hua Xiao; Zhong He; Ke Jin; Cong Ma; Jun Xiang; Jian-Hua Xiao; Wei-Jian Chen
Journal:  Jpn J Radiol       Date:  2012-12-13       Impact factor: 2.374

9.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

Review 10.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.